title: Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.
abstract: Inflammatory bowel disease affects millions of individuals; nevertheless, pharmacological treatment is disappointingly unsatisfactory. Cannabidiol, a safe and non-psychotropic ingredient of marijuana, exerts pharmacological effects (e.g., antioxidant) and mechanisms (e.g., inhibition of endocannabinoids enzymatic degradation) potentially beneficial for the inflamed gut. Thus, we investigated the effect of cannabidiol in a murine model of colitis. Colitis was induced in mice by intracolonic administration of dinitrobenzene sulfonic acid. Inflammation was assessed both macroscopically and histologically. In the inflamed colon, cyclooxygenase-2 and inducible nitric oxide synthase (iNOS) were evaluated by Western blot, interleukin-1beta and interleukin-10 by ELISA, and endocannabinoids by isotope dilution liquid chromatography-mass spectrometry. Human colon adenocarcinoma (Caco-2) cells were used to evaluate the effect of cannabidiol on oxidative stress. Cannabidiol reduced colon injury, inducible iNOS (but not cyclooxygenase-2) expression, and interleukin-1beta, interleukin-10, and endocannabinoid changes associated with 2,4,6-dinitrobenzene sulfonic acid administration. In Caco-2 cells, cannabidiol reduced reactive oxygen species production and lipid peroxidation. In conclusion, cannabidiol, a likely safe compound, prevents experimental colitis in mice.
authors.affiliation: Department of Experimental Pharmacology, University of Naples Federico II, via D Montesano 49, 80131 Naples, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Borrelli
authors.forename: Gabriella
authors.initials: G
authors.lastname: Aviello
authors.forename: Barbara
authors.initials: B
authors.lastname: Romano
authors.forename: Pierangelo
authors.initials: P
authors.lastname: Orlando
authors.forename: Raffaele
authors.initials: R
authors.lastname: Capasso
authors.forename: Francesco
authors.initials: F
authors.lastname: Maiello
authors.forename: Federico
authors.initials: F
authors.lastname: Guadagno
authors.forename: Stefania
authors.initials: S
authors.lastname: Petrosino
authors.forename: Francesco
authors.initials: F
authors.lastname: Capasso
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Di Marzo
authors.forename: Angelo A
authors.initials: AA
authors.lastname: Izzo
mesh_terms: D000581:Amidohydrolases / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D018938:Caco-2 Cells; D002185:Cannabidiol / Q000494:pharmacology / Q000627:therapeutic use*; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism; D002188:Cannabis / Q000737:chemistry*; D002470:Cell Survival / Q000187:drug effects; D003092:Colitis / Q000517:prevention & control*; D003106:Colon / Q000187:drug effects / Q000473:pathology; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics / Q000378:metabolism; D053583:Interleukin-1beta / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D052247:Nitric Oxide Synthase Type II / Q000235:genetics / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D000099252:Fatty Acid Amide Hydrolases
chemical_list: D000581:Amidohydrolases; D000975:Antioxidants; D002185:Cannabidiol; D063385:Cannabinoid Receptor Modulators; D051546:Cyclooxygenase 2; D016753:Interleukin-10; D053583:Interleukin-1beta; D052247:Nitric Oxide Synthase Type II; D000099252:Fatty Acid Amide Hydrolases
references.citation: Pharmacology. 1980;21(3):175-85
references.pmid: 7413719
references.citation: Gastroenterology. 2002 Dec;123(6):2140-4
references.pmid: 12454869
references.citation: Br J Pharmacol. 2000 Aug;130(8):1949-59
references.pmid: 10952687
references.citation: Br J Pharmacol. 2008 Jan;153(2):199-215
references.pmid: 17828291
references.citation: Br J Pharmacol. 2007 Aug;151(8):1272-9
references.pmid: 17592514
references.citation: Nature. 2007 Jul 26;448(7152):427-34
references.pmid: 17653185
references.citation: Biochem Pharmacol. 2002 Jul 1;64(1):1-8
references.pmid: 12106600
references.citation: Gut. 2006 Oct;55(10):1373-6
references.pmid: 16966693
references.citation: J Pharmacol Exp Ther. 2006 Sep;318(3):1375-87
references.pmid: 16728591
references.citation: Am J Pathol. 2006 Jan;168(1):235-44
references.pmid: 16400026
references.citation: FASEB J. 2006 Mar;20(3):568-70
references.pmid: 16403786
references.citation: Inflammopharmacology. 2007 Oct;15(5):188-95
references.pmid: 17943250
references.citation: Br J Pharmacol. 2008 Mar;153(6):1272-80
references.pmid: 18223666
references.citation: Methods Enzymol. 1990;186:407-21
references.pmid: 2233308
references.citation: Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G364-71
references.pmid: 16574988
references.citation: Gastroenterology. 1998 Aug;115(2):297-306
references.pmid: 9679035
references.citation: Gastroenterology. 2006 Mar;130(3):940-87
references.pmid: 16530532
references.citation: Br J Pharmacol. 2008 Jul;154(5):1001-8
references.pmid: 18469842
references.citation: J Mol Med (Berl). 2008 Jan;86(1):89-98
references.pmid: 17823781
references.citation: Gastroenterology. 2005 Sep;129(3):941-51
references.pmid: 16143133
references.citation: J Mol Med (Berl). 2006 Mar;84(3):253-8
references.pmid: 16389547
references.citation: J Neurochem. 2008 Feb;104(4):1091-100
references.pmid: 18028339
references.citation: Nat Prod Rep. 1999 Apr;16(2):131-43
references.pmid: 10331283
references.citation: Gut. 2000 Mar;46(3):344-9
references.pmid: 10673295
references.citation: J Clin Invest. 1996 Nov 1;98(9):2076-85
references.pmid: 8903327
references.citation: Chem Biodivers. 2007 Aug;4(8):1678-92
references.pmid: 17712814
references.citation: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references.pmid: 6606682
references.citation: J Clin Invest. 2004 Apr;113(8):1202-9
references.pmid: 15085199
references.citation: Nat Rev Drug Discov. 2008 May;7(5):438-55
references.pmid: 18446159
references.citation: Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H610-9
references.pmid: 17384130
references.citation: Biosci Biotechnol Biochem. 2006 Jun;70(6):1317-24
references.pmid: 16794309
references.citation: Gut. 2008 Apr;57(4):429-33
references.pmid: 18079284
references.citation: ScientificWorldJournal. 2006 May 25;6:577-88
references.pmid: 16752007
references.citation: Br J Pharmacol. 2008 Jan;153(2):263-70
references.pmid: 17906675
references.citation: Br J Pharmacol. 2007 Nov;152(5):583-93
references.pmid: 17641667
references.citation: Cancer Res. 1991 Jan 1;51(1):77-81
references.pmid: 1988109
references.citation: Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8268-73
references.pmid: 9653176
references.citation: J Mol Med (Berl). 2008 Aug;86(8):925-36
references.pmid: 18493729
references.citation: Gut. 2008 Aug;57(8):1140-55
references.pmid: 18397936
references.citation: Neurogastroenterol Motil. 2008 Aug;20(8):919-27
references.pmid: 18373655
references.citation: Immunology. 2004 Dec;113(4):427-37
references.pmid: 15554920
references.citation: Aliment Pharmacol Ther. 2002 Dec;16(12):1997-2015
references.pmid: 12452933
references.citation: Gastroenterology. 1992 Jul;103(1):65-71
references.pmid: 1535326
references.citation: World J Gastroenterol. 2008 Jan 21;14(3):354-77
references.pmid: 18200659
references.citation: Eur J Pharmacol. 2007 Feb 5;556(1-3):75-83
references.pmid: 17157290
references.citation: Br J Pharmacol. 2001 Oct;134(4):845-52
references.pmid: 11606325